Citalopram hydrobromide (XU-62-320) , a selective serotonin reuptake inhibitor (SSRI), selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). Citalopram hydrobromide is the orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).

5-HT receptor:1.8 nM

Citalopram(Lu 10-171)，一种新型双环邻苯二甲酸衍生物，是一种极具有力的神经元5-羟色胺(5-HT)摄取抑制剂，但对去甲肾上腺素(NA)和多巴胺(DA)的摄取无影响，且不对5-HT、组胺、γ-氨基丁酸(GABA)、乙酰胆碱及吗啡受体表现出拮抗活性。它是一个极其特异和有力的神经元5-HT摄取抑制剂。其他递质胺的摄取机制不受该化合物影响。Citalopram 作为SSRI，对细胞增殖具有更大的影响，对凋亡活性的影响较小。它通过增加增殖潜力和降低凋亡活动、在特定部位以可能表明增生的方式，影响细胞周期调控。Citalopram 改变了成骨细胞培养中的FGF、MSX和TGFB表达。

Citalopram 即使在動物暴露於遠高於治療水平的濃度時，也不會導致心臟毒性效應。在人體中，Citalopram 被代謝成同樣具有強大5-HT攝取抑制作用的化合物，但不影響去甲腎上腺素(NA)的攝取，且這些化合物的濃度低於Citalopram 本身。Citalopram (1-16 mg/kg)能刺激脊髓大鼠的後肢屈肌反射。Citalopram 可能通過產生非常強的攝取抑制作用而增強5-HT傳導，同時不阻塞5-HT的突觸後受體[1]。

Cells are cultured in alpha minimum Eagles medium supplemented with 1% penicillin/streptomycin, 10% fetal bovine serum and Amphotericin B. For control data, cells are cultured for 3 or 7 days with standard alpha proliferation media. For SSRI treatments, media is supplemented with citalopram eluted to serially diluted doses between 10?4 mol through 10?10 mol to achieve a dose response curve.(Only for Reference)